IMCAS Paris 2025 Recap: Key Topics and Trends

IMCAS Paris 2025 once again served as a global hub for aesthetic medicine, uniting industry leaders, medical professionals, and innovators to explore the latest trends and advancements. Held from January 30 to February 1 at the Palais des Congrès in Paris, the event attracted over 20,000 HCPs who engaged with 1,000 speakers and 370 exhibitors.

The Hubmed team was there on the spot to bring you key insights from the conference. 

Key Takeaways

• Regenerative Aesthetics on the Rise: Prollenium, Unilever, and other brands introduced next-gen skin regeneration solutions, including PDRN and exosomes, signaling a shift toward cellular repair and long-term rejuvenation.
• Neuromodulator Innovations: Galderma’s RelabotulinumtoxinA (Relfydess™) promises rapid onset and extended longevity.
• Combination Treatments Gaining Traction: IMCAS expert presentors highlighted the effectiveness of blending neurotoxins, fillers, biostimulators, and energy-based devices to address aging comprehensively.
• Skin Quality Over Volume: The industry is prioritizing skin health, with tailored treatment protocols (e.g., Galderma’s Restylane Skinboosters and Sculptra) focusing on elasticity, hydration, and texture improvement.‍
• GLP-1 Weight Loss Drugs Impact Aesthetics: Rapid weight loss from Ozempic and similar drugs is increasing skin laxity concerns, leading to a greater demand for biostimulators, RF, PRP, and thread lifts to restore skin firmness.

Updates from Leading Aesthetic Companies

As always, the key industry players came prepared with a few announcements. Here are the highlights from the IMCAS Paris 2025 most attended brand symposiums:

Prollenium: Next-Gen Skin Regeneration Technologies

Prollenium, the company behind the renowned Revanesse dermal filler line, is taking a bold step forward in regenerative aesthetics. At IMCAS 2025, the brand announced a strategic shift toward cutting-edge skin rejuvenation solutions, focusing on PDRN, exosome-based therapies, and collagen-stimulating biostimulants. With a vertically integrated manufacturing process and a dedicated in-house R&D incubator, Prollenium is set to redefine skin health by targeting cellular repair and long-term regeneration.

Galderma: Updates on RelabotulinumtoxinA (Relfydess™)

Galderma presented new Phase IIIb data supporting the rapid onset and extended longevity of RelabotulinumtoxinA, their upcoming liquid neuromodulator currently undergoing EU approval. This product, designed with PEARL Technology for optimized volumetric dosing, promises results lasting beyond six months, with effects visible as early as Day 1.

Teoxane: A Decade of RHA Gels

Celebrating the 10-year anniversary of Teyosal RHA gels, Dr. Sabrina Shah Desai shared the four secrets behind their preserved network technology. These include gentle mixing conditions, heathless crosslinking, no small HA fragments, and very high MW-free HA addition. Teoxane’s technology allows their products to preserve the HA chain length, improving their flexibility and allowing for more natural-looking results. 

Unilever: Introduction of the Bacterial-Based Exosomes

Dr. Robert Bianchini, Unilever’s R&D vice president, presented Dermatologica PRO Exo Booster, the bacterial exosomes that are supposed to be superior to human-retreived exosomes for aesthetic procedures. Their new Exo Booster is a bi-phase treatment that works as a result amplifier for other aeshtetic treatments. Its key ingredients include: 10 billion skin-rejuvenating exosomes in each treatment, Omega 3, Bacillus Ferment and Niacinamide that strenghten skin barrier, Phospolopides from Olive Stem Cells and Oligopeptide-1 that visibly improve firmness. 

Vivacy: Taking a Step Further with HA Fillers

The Vivacy symposium showcased the results of Stylage® HA-based fillers application in patients needing restoration and/or facial volume augmentation. The staple in their portfolio, Stylage® Hydromax, has shown excellent results in restoring skin quality as well. This product’s exclusive formula with 12,5mg/ml of HA is based on cross-linked HA, free HA of high molecular weight, and sorbitol-enriched buffer. In a live survey conducted during the symposium, the majority of attendees agreed that HA should be included in the biostimulation family.

Allergan: AA Signature Program Launch

Allergan Aesthetics introduced the AA Signature Program, a holistic approach to treatment planning that emphasizes lift, definition, and skin quality. Research presented by Prof. Reha Yavuzer indicates that clinics utilizing multimodal treatment approaches experience a 68% higher patient retention rate. To deliver tailored solutions, the program incorporates well-known products like Juvederm®, HArmonyCa®, and Botox®.

Merz Aesthetics: Study on Psychological Benefits of Aesthetic Treatments

Merz presented the findings from their Pillars of Confidence study, which surveyed 15,000 individuals globally. The study found that 69% of patients pursue aesthetic treatments to align their appearance with their internal self-image, while 72% reported that these treatments positively influenced their self-perception. This underscores the emotional and psychological impact of aesthetic interventions in clinical practice.

Current and Emerging Trends

Here are the key trends and insights that are set to shape the industry in the coming year:

1. Demand for Natural Look

Patients are becoming more cautious about dermal fillers, with growing awareness of the Overfilled Syndrome (OFS). As mentioned in the IMCAS Teoxane Symposium, OFS can be both patient and injector-led. Patient can come with unrealistic treatment expectations, where it’s up to the injector to educate them on realistic outcomes. On the other hand, if the injector has poor knowledge of the facial anatomy, chooses the wrong product, or uses an improper technique, the patient may end up with a “pillow face.” Continuing education on both sides is necessary for achieving a natural-looking outcomes.

2. Focus on Skin Quality

Beyond volumization, aesthetic professionals are now prioritizing treatments that enhance overall skin quality. Several manufacturers presented their own solutions for skin quality improvement. For example, Galderma’s skin quality protocol includes:

• Use of Restylane Skinboosters for patients with relatively firm / midly atrophic skin. The initial treatment can be followed up with Sculptra protocol to prevent the loss of elasitciy over time.
• Use of Sculptra for patients with prominent loss of elasticity and contour deformities. If patients has also residual fine lines, wrinkles, scars and enlarged pores, second step would include Restylane Skinboosters. Patients without particularly dry skin are advised to continue with a skincare regimen.

3. Combination Treatments

One of the strongest trends emerging from IMCAS 2025 is the increasing emphasis on combination treatments to achieve superior, longer-lasting results. Several manufacturers presented their protocols for combining multiple products in a same day session or during the follow up treatments. 

Rather than relying on a single modality, practitioners are now blending neurotoxins, fillers, biostimulators, and energy-based devices to address multiple layers of aging simultaneously. Allergan’s AA Signature program supports this shift by integrating assessment tools, and product combinations for customized patient plans.

4. Skin Laxity and the GLP-1 Effect on Skin

As the increased use of Ozempic, Mounjaro, and similar weight-loss medications continues, practitioners are seeing more cases of skin laxity due to rapid weight loss. Previously, we focused more on restoring the lost volume with volumizing HA fillers, which are not sufficient fix for skin laxity. Now, biostimulators like Radiesse and Sculptra, alongside RF, PRP, and thread lifts, proven to be essential solutions for this concern, working in harmony to improve the skin laxity.

5. Exosomes and Regenerative Aesthetics

The use of PDRN and exosomes in skin rejuvenation and hair loss treatment continues to gain significant attention. New plant- and bacterial-based exosome formulations were introduced, offering ethical and stable alternatives to human-derived exosomes. However, some challenges still remain, like exosomes cell-line development, upstream cell culture, downstream purification process, products shelf life, and regulatory considerations.

Continue Learning with Hubmed

At Hubmed, we're not only committed to keeping you updated on these advancements but also offer valuable resources to help you enhance your skills. Our VODs on injections and expert-led masterclasses provide in-depth training on the latest techniques and treatments, empowering you to stay ahead in the field. Stay tuned for more from Hubmed as we continue to support your journey in aesthetics.